Minocycline HCl
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317115

CAS#: 13614-98-7 (HCl)

Description: Minocycline (INN) is a broad-spectrum tetracycline antibiotic, and has a broader spectrum than the other members of the group. It is a bacteriostatic antibiotic, classified as a long-acting type. As a result of its long half-life it generally has serum levels 2–4 times that of the simple water-soluble tetracyclines (150 mg giving 16 times the activity levels compared with 250 mg of tetracycline at 24–48 hours). Minocycline is the most lipid-soluble of the tetracycline-class antibiotics, giving it the greatest penetration into the prostate and brain. Minocycline is not a naturally-occurring antibiotic, but was synthesized semi-synthetically from natural tetracycline antibiotics by Lederle Laboratories in 1966. (https://en.wikipedia.org/wiki/Minocycline) )


Chemical Structure

img
Minocycline HCl
CAS# 13614-98-7 (HCl)

Theoretical Analysis

MedKoo Cat#: 317115
Name: Minocycline HCl
CAS#: 13614-98-7 (HCl)
Chemical Formula: C23H28ClN3O7
Exact Mass:
Molecular Weight: 493.94
Elemental Analysis: C, 55.93; H, 5.71; Cl, 7.18; N, 8.51; O, 22.67

Price and Availability

Size Price Availability Quantity
1.0g USD 150.0 Same day
2.0g USD 250.0 Same day
5.0g USD 450.0 Same day
10.0g USD 650.0 Same day
20.0g USD 1150.0 Same day
50.0g USD 1950.0 Same day
100.0g USD 2950.0 2 Weeks
200.0g USD 4650.0 2 Weeks
1.0kg USD 9650.0 2 Weeks
Click to view more sizes and prices
Bulk inquiry

Related CAS #: 13614-98-7 (HCl)   10118-90-8 (free base)    

Synonym: Minocycline HCl; NSC 141993; Mynocine hydrochloride; Periocline; Klinomycin; Minocin; Solodyn; Tri-mino; Vectrin; Ximino;

IUPAC/Chemical Name: (4S,4aR,5aS,12aR,E)-2-(amino(hydroxy)methylene)-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5a,6,12a-tetrahydrotetracene-1,3,12(2H,4H,5H)-trione hydrochloride

InChi Key: KDLQIOPKJDNQIM-YKWOUSISSA-N

InChi Code: InChI=1S/C23H27N3O7.ClH/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28;/h5-6,9,11,17,27-28,32-33H,7-8,24H2,1-4H3;1H/b22-16+;/t9-,11-,17+,23-;/m1./s1

SMILES Code: O=C([C@@]1(O)[C@@](C[C@]2([H])C(C1=O)=C(O)C3=C(O)C=CC(N(C)C)=C3C2)([H])[C@@H]4N(C)C)/C(C4=O)=C(N)/O.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 493.94 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Doughty MJ. On the prescribing of oral doxycycline or minocycline by UK optometrists as part of management of chronic Meibomian Gland Dysfunction (MGD). Cont Lens Anterior Eye. 2015 Sep 4. pii: S1367-0484(15)30020-5. doi: 10.1016/j.clae.2015.08.002. [Epub ahead of print] Review. PubMed PMID: 26347083.

2: Dean OM, Maes M, Ashton M, Berk L, Kanchanatawan B, Sughondhabirom A, Tangwongchai S, Ng C, Dowling N, Malhi GS, Berk M. Protocol and Rationale-The Efficacy of Minocycline as an Adjunctive Treatment for Major Depressive Disorder: A Double Blind, Randomised, Placebo Controlled Trial. Clin Psychopharmacol Neurosci. 2014 Dec;12(3):180-188. Epub 2014 Dec 26. Review. PubMed PMID: 25598820; PubMed Central PMCID: PMC4293162.

3: Ritchie DJ, Garavaglia-Wilson A. A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections. Clin Infect Dis. 2014 Dec 1;59 Suppl 6:S374-80. doi: 10.1093/cid/ciu613. Review. PubMed PMID: 25371513.

4: Sheu J, Saavedra AP, Mostaghimi A. Rapid response of tattoo-associated cutaneous sarcoidosis to minocycline: case report and review of the literature. Dermatol Online J. 2014 Aug 17;20(8). pii: 13030/qt6dd1m2j9. Review. PubMed PMID: 25148277.

5: Oya K, Kishi T, Iwata N. Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Hum Psychopharmacol. 2014 Sep;29(5):483-91. Review. PubMed PMID: 25087702.

6: Zhang L, Zhao J. Profile of minocycline and its potential in the treatment of schizophrenia. Neuropsychiatr Dis Treat. 2014 Jun 17;10:1103-11. doi: 10.2147/NDT.S64236. eCollection 2014. Review. PubMed PMID: 24971013; PubMed Central PMCID: PMC4069141.

7: Hovens JE, Onderwater TA. [Minocycline for schizophrenia: a brief overview]. Tijdschr Psychiatr. 2014;56(6):402-6. Review. Dutch. PubMed PMID: 24953514.

8: Chen JS, Chan WK, Yang PC. Intrapleural minocycline pleurodesis for the treatment of primary spontaneous pneumothorax. Curr Opin Pulm Med. 2014 Jul;20(4):371-6. doi: 10.1097/MCP.0000000000000067. Review. PubMed PMID: 24852327.

9: Neonakis IK, Spandidos DA, Petinaki E. Is minocycline a solution for multidrug-resistant Acinetobacter baumannii? Future Microbiol. 2014;9(3):299-305. doi: 10.2217/fmb.13.167. Review. PubMed PMID: 24762305.

10: Nakajima T, Taniwaka K, Yoshioka T, Abe S, Kamei T, Goto H. [A case of carcinomatous cardiac tamponade caused by breast cancer treated with instillation of paclitaxel and minocycline]. Gan To Kagaku Ryoho. 2014 Jan;41(1):87-9. Review. Japanese. PubMed PMID: 24423958.

11: Nakamura J, Sugawara H, Ishii A, Tsukahara R, Demitsu T, Sanayama H, Watanabe T, Nokubi M. [Case report; a case of minocycline-induced polyarteritis nodosa with fever, arthralgia, and erythema on bilateral lower extremities]. Nihon Naika Gakkai Zasshi. 2013 Aug 10;102(8):2053-6. Review. Japanese. PubMed PMID: 24167867.

12: Cunha BA. Minocycline, often forgotten but preferred to trimethoprim-sulfamethoxazole or doxycycline for the treatment of community-acquired meticillin-resistant Staphylococcus aureus skin and soft-tissue infections. Int J Antimicrob Agents. 2013 Dec;42(6):497-9. doi: 10.1016/j.ijantimicag.2013.08.006. Epub 2013 Sep 13. Review. PubMed PMID: 24126085.

13: Li C, Yuan K, Schluesener H. Impact of minocycline on neurodegenerative diseases in rodents: a meta-analysis. Rev Neurosci. 2013;24(5):553-62. doi: 10.1515/revneuro-2013-0040. Review. PubMed PMID: 24077620.

14: Liao TV, Forehand CC, Hess DC, Fagan SC. Minocycline repurposing in critical illness: focus on stroke. Curr Top Med Chem. 2013;13(18):2283-90. Review. PubMed PMID: 24059465.

15: Parr K, Mahmoudizad R, Grimwood R. Resolution of radiation-induced acneform eruption following treatment with tretinoin and minocycline: a case report. Cutis. 2013 Jul;92(1):27-8. Review. PubMed PMID: 23961521.

16: Hashimoto K, Ishima T, Fujita Y, Zhang L. [Antibiotic drug minocycline: a potential therapeutic drug for methamphetamine-related disorders]. Nihon Arukoru Yakubutsu Igakkai Zasshi. 2013 Apr;48(2):118-25. Review. Japanese. PubMed PMID: 23808319.

17: Lenert P, Icardi M, Dahmoush L. ANA (+) ANCA (+) systemic vasculitis associated with the use of minocycline: case-based review. Clin Rheumatol. 2013 Jul;32(7):1099-106. doi: 10.1007/s10067-013-2245-z. Epub 2013 Apr 21. Review. PubMed PMID: 23604593.

18: Garrido-Mesa N, Zarzuelo A, Gálvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol. 2013 May;169(2):337-52. doi: 10.1111/bph.12139. Review. PubMed PMID: 23441623; PubMed Central PMCID: PMC3651660.

19: Kerbleski GJ, Hampton TT, Cornejo A. Black bone disease of the foot: a case study and review of literature demonstrating a correlation of long-term minocycline therapy and bone hyperpigmentation. J Foot Ankle Surg. 2013 Mar-Apr;52(2):239-41. doi: 10.1053/j.jfas.2012.10.018. Epub 2013 Jan 9. Review. PubMed PMID: 23312403.

20: Zur E. Recurrent aphthous stomatitis: topical treatment with minocycline and other evidence-based agents. Int J Pharm Compd. 2012 Nov-Dec;16(6):462-9. Review. PubMed PMID: 23259361.